Heidi R Hope - Confluence Discovery Technol Inc

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 12 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis Without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201

Paul Changelian,Canxin Xu,Steve Mnich,Heidi Hope,Kourtney Kostecki,Jeff Hirsch, Chin-Yi Loh,David Anderson, James Blinn,Susan Hockerman, Evan Dick,Walter Smith,Joseph Monahan, Tooraj Raoof, Seth Forman,David Burt, Brad Barnes,David Gordon,Neal Walker, John Sudzina

JID Innovationsno. 2 (2024): 100251

Cited0Views0WOSBibtex

ATI-450: A Novel MK2 Pathway Inhibitor - Preclinical & Clinical Translational Studies to Predict Human Dose

Heidi R. Hope,Susan Hockerman, Matt Saabye, Loreen Stillwell, Rakesh Basavalingappa, Catherine Emanual,Steve Mnich, Madison Bangs, Emma Huff, Aparna Kaul, Anne Hildebrand,Marco Cardillo,Ajay Aggarwal,Joseph B. Monahan

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Cited0Views0Bibtex

ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450+MTX vs PBO plus MTX in MTX IR Patients

Alan Kivitz, Joe Monahan,David Burt,Marco Cardillo,Heidi Hope,David Gordon

ARTHRITIS & RHEUMATOLOGY（2021）

Cited0Views0Bibtex

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase I Study

David Gordon,Edward T. Hellriegel,Heidi Rath Hope,David Burt,Joseph B. Monahan

Clinical Pharmacology Advances and Applications（2021）

Cited11Views0WOSBibtex

Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals

Chun Wang,Susan Hockerman,E Jon Jacobsen,Yael Alippe,Shaun R Selness,Heidi R Hope,Jeffrey L Hirsch,Stephen J Mnich,Matthew J Saabye,William F Hood,Sheri L Bonar,Yousef Abu-Amer,Ariela Haimovich,Hal M Hoffman,Joseph B Monahan,Gabriel Mbalaviele

JOURNAL OF EXPERIMENTAL MEDICINE（2018）

Cited59Views0WOSBibtex

Discovery of Clinical Candidate 1-{[(2S,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Journal of medicinal chemistry（2017）

Cited108Views0WOSBibtex

108

Nomid-Associated Complications In Mice Are Prevented By Cdd-450, A Small Molecule Inhibitor Of The Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (Mk2) Pathway

Gabriel Mbalaviele,Chun Wang,Susan Hockerman,Jon Jacobsen,Jeff Hirsch,Steve Mnich,Heidi Hope, Matt Saabye,Hal Hoffman,Joseph Monahan

ARTHRITIS & RHEUMATOLOGY（2017）

Cited0Views0Bibtex

A selective p38 MAPK-MK2 axis inhibitor dampens inflammasome priming signals and causes remarkable efficacy in disease models

Chun Wang, Yael Allipe,Jianqiu Xiao,Susan Hockerman,Jon Jacobsen,Heidi Hope,Jeff Hirsch,Steve Mnich, Matt Saabye,Sheri Bonar,Hal Hoffman,Joseph Monahan,Gabriel Mbalaviele

JOURNAL OF BONE AND MINERAL RESEARCH（2017）

Cited0Views0Bibtex

Interleukin-1β-induced Interleukin-6 Production in A549 Cells is Mediated by Both Phosphatidylinositol 3-Kinase and Interleukin-1 Receptor-Associated Kinase-4

Hiroyuki Eda,Barry L. Burnette,Hideaki Shimada,Heidi R. Hope,Joseph B. Monahan

Cell biology international（2011）

Cited24Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn